Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Raised
$48M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Team Size
1–10
Employees
$48,000,000 Venture capital (Series A)
Xconomy

Palleon Lands $48M to Develop New Type of Checkpoint Cancer Drug

Health Science Funding